Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type( ~- M" ]6 z G0 J
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
5 Q& c! b" ]) _% j7 N2 o$ E+ Author Affiliations
" f# }2 E% |. z! n* U/ q' g! [* a2 C6 G% F1 D( `9 S$ E
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
* z' I3 I& c) \; e) X, V) B2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; U' |, S: D; ]; d' K3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " Y! _$ w v/ \" c+ g% h! J( i0 G7 s
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan , \5 y; f; A) X+ b t/ z, t; ]
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 0 w: w6 X% B3 X* K* Z
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
2 L: C$ ?0 d3 ^) D' W4 v7Kinki University School of Medicine, Osaka 589-8511, Japan * V3 ~! S4 r8 Q6 f* w$ h% m
8Izumi Municipal Hospital, Osaka 594-0071, Japan ! t h B9 x. X8 G4 ~4 F
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan + K! q. G" ?+ N! k% A% v
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp : G7 S5 u# e3 e0 R
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 2 S3 a* Z. Q0 H$ W7 @7 Z3 b
) z* {4 y" i( m' u |